Use of composite scores in the quantification of deterioration in multiple sclerosis

Kurtzke JF. (1983) Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS) . Neurology 33: 1444-1452 .

Weinshenker BG. (1996) Clinical outcome measures for multiple sclerosis. In: Goodkin DE , Rudick RA , eds. Multiple sclerosis: advances in clinical trial design, treatment, and future perspectives. Springer: London , pp 105-122.

Petkau AJ. (1996) Statistical and design considerations for multiple sclerosis clinical trials. In: Goodkin DE , Rudick RA , eds. Multiple sclerosis: advances in clinical trial design, treatment and future perspectives. Springer: London , pp 63-103.

Whitaker JN , McFarland HF , Rudge P , Reingold SC. (1995) Outcomes assessment in multiple sclerosis clinical trials: a critical analysis . Multiple Sclerosis 1: 37-47 .

Sharrack B , Hughes RAC. (1996) Clinical scales for multiple sclerosis . J Neurol Sci 135: 1-9 .

Goodkin DE et al. (1996) Low-Dose (7.5 mg) oral Methotrexate reduces the rate of progression in chronic progressive Multiple Sclerosis . Ann Neurol 37: 30-40 .

Rudick R et al. (1996) Clinical outcomes assessment in multiple sclerosis . Ann Neurol 40: 469-479 .

Rudick R et al. (1997) Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force . Ann Neurol 42: 379-382 .